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Abstract
Background: Supportive-care use of granulocyte colony-stimulating factor (G-CSF) in pediatric
acutemyeloid leukemia (AML) remains controversial due to a theoretical increased risk of relapse
and limited impact on neutropenic complications. We describe the use of G-CSF in patients
treated according to NOPHO-AML 2004 and DB AML-01 and investigated associations with
relapse.
Procedure: Patients diagnosed with de novo AML completing the first week of therapy and
not treated with hematopoietic stem cell transplantation in the first complete remission were
included (n = 367). Information on G-CSF treatment after each course (yes/no) was registered
prospectively in the study database and detailed information was gathered retrospectively from
each center. Descriptive statistics were used to describe G-CSF use and Cox regression to assess
the association between G-CSF and risk of relapse.
Results:G-CSF as supportive care was given to 128 (35%) patients after 268 (39%) courses, with
a large variation between centers (0-93%). The use decreased with time—the country-adjusted
odds ratio was 0.8/diagnostic year (95% confidence interval [CI] 0.7-0.9). The median daily dose
was 5 𝜇g/kg (range 3-12 𝜇g/kg) and the median cumulative dose was 75 𝜇g/kg (range 7-1460
𝜇g/kg). Filgrastim was used in 82% of G-CSF administrations and infection was the indication in
44%ofG-CSF administrations. G-CSFwas associatedwith increased risk of relapse—the adjusted
hazard ratio was 1.5 (95%CI 1.1-2.2).
Abbreviations: AML, acutemyeloid leukemia; BMI, bodymass index; CI, confidence interval; G-CSF, granulocyte colony-stimulating factor; HSCT, hematopoietic stem cell transplantation; ITD,
internal tandem duplication; OR, odds ratio.
Pediatr Blood Cancer. 2019;e27701. c© 2019Wiley Periodicals, Inc. 1 of 8wileyonlinelibrary.com/journal/pbc
https://doi.org/10.1002/pbc.27701
2 of 8 LØHMANN ET AL.
Conclusions: G-CSF as supportive care was used in a third of patients, and use decreased with
time. Our results indicate that the use of G-CSF may be associated with an increased risk of
relapse.
K EYWORDS
AML, G-CSF, pediatric, relapse
1 INTRODUCTION
Treatment for pediatric acute myeloid leukemia (AML) is highly toxic
and 5-10% of patients die as a consequence of treatment.1–7 Infec-
tions during neutropenia are the most frequent cause of treatment-
related mortality and a major cause of morbidity.1,2,4,6–8 Granulocyte
colony-stimulating factor (G-CSF) has been used to decrease time
with neutropenia, aiming to reduce severe infections and treatment-
relatedmortality. Yet, whileG-CSF has been shown to reduce the dura-
tion of neutropenia in children treated for cancer,9 the use of G-CSF
in AML remains controversial. This is due to reports showing that
myeloid leukemia cells express G-CSF receptors and that G-CSF can
stimulate proliferation of leukemic blasts in vitro.10,11 Furthermore,
an increased risk of relapse has been shown in patients receiving G-
CSF and overexpressing G-CSFR isoform IV.12 G-CSF does not seem to
reduce microbiologically documented infections or treatment-related
mortality.13,14 The general use of G-CSF for prevention of infectious
complications in children or adults during treatment is currently not
recommended.15,16
In the last concluded Nordic and Dutch-Belgian pediatric AML pro-
tocols (NOPHO-AML 2004 and DB AML-01), G-CSF was not part of
standard recommendations but could be administered according to
physician preference. In this study, we aimed to describe supportive-
care G-CSF use including indications and cumulative doses in children
treated according to NOPHO-AML 2004 and DB AML-01. Secondly,
we aimed to investigate associations between G-CSF treatment and
risk of relapse.
2 MATERIALS AND METHODS
2.1 Patients
Patients treated according to NOPHO-AML 2004 and DB AML-01
were eligible for this study. The protocols were population based in
children less than 15 years of age (for some centers, less than 18
years) diagnosed with AML in the five Nordic countries (Denmark,
Finland, Iceland, Norway, and Sweden) from 2004 to 2013 (NOPHO-
AML 2004), in Hong Kong from 2007 to 2013 (NOPHO-AML 2004), in
Belgium from 2010 to 2014 (DB AML-01), and the Netherlands from
2010 to 2013 (DB AML-01). Children with Down syndrome, acute
promyelocytic leukemia, isolated granulocytic sarcoma, or secondary
AML were excluded. Further exclusion criteria for this study were (a)
death within the first week after starting treatment and (b) treatment
with hematopoietic stem cell transplantation (HSCT) in the first com-
plete remission (CR1).
2.2 Protocols
Protocol details for NOPHO-AML 2004 and DB AML-01 including
drug doses have been published previously.17–19 The NOPHO-AML
2004 protocol consisted of two induction courses (AIET and AM) and
four consolidation courses (HA1M, HA2E1, HA3, and HA2E2) followed
by a randomization to gemtuzumab ozogamicin or no further therapy.
Children not in remission after two induction courseswere given FLAG
as a third induction course, whereas those in remission proceeded to
consolidation therapy. G-CSF given as a part of FLAG was not consid-
ered supportive care, and is therefore not included in this study. High-
risk patients (bone marrow blasts >15% after AIET or no remission
after second induction course or the presence of KMT2A rearrange-
ments other than t[9;11][p21;q23]) were offered allogeneic HSCT. The
following threeamendmentsweremadeduring theprotocol period: (1)
In 2009, the high-risk criteria were restricted to poor response only,
(2) in 2011, FLT3 with internal tandem duplication (FLT3/ITD) without
NPM1mutations became a high-risk criterion, and (3) in 2011, the sec-
ond induction coursewas changed fromAMto FLA-Dx in patientswith
t(8;21) or bonemarrow blasts 5-15% on day 15.20
The DB AML-01 protocol was similar to NOPHO-AML 2004, and
included the same two induction courses, but only three consolida-
tion courses (HA2E1, HA3, and HA2E2, omitting HA1M). Moreover,
the protocol did not recommend HSCT in CR1 for any patient and did
not include randomization to gemtuzumab ozogamicin. Children not
in remission after two induction courses were taken off protocol. The
protocolswere approvedby thenational ethics committees in the eight
participating countries and written informed consent was obtained
from all patients or their parents or guardians.
2.3 Supportive care
The NOPHO-AML 2004 protocol had recommendations on prophy-
lactic sulfamethoxazole/trimethoprim 2-3 days perweek. Prophylactic
fluconazolewas recommended until 1month after the last chemother-
apy course. No other prophylactic antibacterial or antiviral drugs were
recommended. Use of prophylactic G-CSF was not generally recom-
mended, but G-CSF could be considered in patients with neutrope-
nia and life-threatening infection. The DB AML-01 protocol did not
contain specific recommendations onprophylactic supportive care and
thus prophylactic measures depended on local practice.
2.4 Data collection
Data on demographics, toxicity, and G-CSF administration (yes/no)
after each course and follow-up information were registered prospec-
tively in the joined database for the two protocols by the treating
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physician or local data manager. If data on G-CSF administration were
missing for a course in the protocol database, it was assumed G-CSF
was not given. If G-CSF administration was registered for a patient,
an exploratory questionnaire was sent to the center where the patient
was treated, retrospectively collecting information on G-CSF prepara-
tion, dose, treatment duration, and indication (infection, neutropenia
without infection, prophylactic, or other). The indication was defined
as prophylactic if G-CSF was administered within the first week after
course start. If the daily dose of G-CSF was missing, the patient was
assumed to have received the recommended dose for the cumulative
dose analyses (filgrastim and lenograstim 5 𝜇g/kg/day, pegfilgrastim
100 𝜇g/kg given once).21,22
2.5 Definitions and statistics
Standard deviation score of body mass index (BMI) for age and sex
was calculated according to the World Health Organization growth
standards.23 Chemotherapy dose reductions were defined as more
than a 20% reduction of at least one drug dose or chemotherapy inter-
ruption of more than 7 days not including intrathecal treatment. Mul-
tiple logistic regression was used to assess the association of diagnos-
tic year and G-CSF administration. Cox regression was used to assess
the association between G-CSF administration and risk of relapse. For
this analysis, follow-up started at the last day with absolute neutrophil
count <0.5 × 109/L after the last consolidation course (HA2E2) and
ended at relapse, death, or end of follow-up. This design excluded
treatment-related mortality during therapy. Restricted cubic splines
with three knots (at the 50th, 75th, and 90th percentiles)24 were used
to show the continuous relationship of the cumulative dose of G-CSF
and risk of relapse. Confounders incorporated into statistical mod-
els were defined as factors, which could be a cause of both indepen-
dent and dependent variables, and were selected a priori. Country
was included in the model of diagnostic year and G-CSF administra-
tion. Sex, age (continuous), BMI standard deviation score (continuous),
t(8;21) (yes/no), inv(16) (yes/no), KMT2A rearrangements (yes/no),
FLT3/ITD status (FLT3/ITD yes/no), response to first induction (≥5%
blasts betweenday15and start of second induction) (yes/no), anddose
reductions (yes/no) were included as covariates in the adjusted model
of G-CSF treatment and risk of relapse. Missing values for FLT3 status
(24%) were handled by multiple imputation for the analysis of G-CSF
treatment and risk of relapse; for details, see Supplementary Material
S1. All tests of significance were two sided. Statistical significance was
defined as P< 0.05.
3 RESULTS
3.1 G-CSF treatment in NOPHO-AML 2004
andDBAML-01
Of the 434 patients registered on NOPHO-AML 2004 and DB
AML-01, five patients died before day 8 and 62 were treated with
HSCT in CR1, and therefore excluded from this study (Figure 1). In
total, 367 patients were included and 128 (35%) received G-CSF as
supportive care at least once during treatment (Figure 1). Four of the
included patients received FLAG as a third induction course. Base-
line characteristics for the cohort are shown in Table 1. Data on G-
CSF administration were missing in the protocol database after AIET
in six (2%) cases, after AM in four (1%) cases, after HA1M in two (1%)
cases, after HA2E1 in 11 (3%) cases, after HA3 in 10 (3%) cases, and
after HA2E2 in 12 (4%) cases. In total, 1979 courses were given (not
including GO and extra induction courses) and G-CSF was given after
269 (14%) courses. In patients that received G-CSF at least once, 695
courses were given followed by G-CSF administration in 269 (39%).
Of the 367 patients in this study, 239 (65%) never received G-CSF, 66
(18%) received it after one course, 17 (5%) after two, 27 (7%) after
three, eight (2%) after four, four (1%) after five, and six (2%) received
G-CSF after six courses of chemotherapy. The use of G-CSF differed
between countries, but even more between centers—in centers that
had treated 10 or more protocol patients, the percentage of patients
that received G-CSF at least once ranged from 0 to 93%. Of patients
treated according to NOPHO-AML 2004, 39% had received G-CSF
at least once, and of patients treated according to DB AML-01, 23%
had received G-CSF at least once. G-CSF use was more common in
patients treated between 2004 and 2009 and in patients with core
binding factor leukemia (t[8;21] or inv[16]/t[16;16]), and less common
in patients treated between 2010 and 2014, with FLT3/ITD and with
KMT2A rearrangements (Table 1). The median cumulative neutrophil
recovery time per course did not correlate with cytogenetic abnor-
malities or FLT3/ITD status (Supplementary Table S2). The odds ratio
(OR) of G-CSF administration decreased with increasing diagnostic
year (crude OR 0.9/diagnostic year, 95% confidence interval [CI] 0.8-
1.0; country-adjustedOR 0.8/diagnostic year, 95%CI 0.7-0.9).
In 19 patients with registered G-CSF use, all or some additional
information was missing (Figure 1). The dose of G-CSF was missing
after 11 courses. In the remaining cases, themedian cumulative G-CSF
dose was 75 𝜇g/kg (range: 7-1460 𝜇g/kg). The median total treatment
durationwas 13 days (range 1-85 days) in patients treatedwith filgras-
tim or lenograstim.
Table 2 shows information on G-CSF treatment per course. G-
CSF treatment was most common after HA1M and FLA-Dx and the
most commonly used drug was filgrastim. The median daily dose of
filgrastim or lenograstim was 5 𝜇g/kg (range 3-12 𝜇g/kg). The most
common indication for treatment was infection. G-CSF treatment
was usually started 2-3 weeks after the start of course if the indica-
tion was infection or neutropenia, but immediately after the end of
chemotherapy if G-CSF was administered prophylactically (Table 2).
The cumulative dose per course was higher if G-CSFwas administered
prophylactically.
3.2 G-CSF treatment and risk of relapse
Of the included patients, 46 did not receive all chemotherapy courses
due to leaving protocol (n = 4), relapse (n = 26), and death (n = 16; not
in CR1 [n = 8]; in CR1 [n = 8]). Of those that received and recovered
from the last consolidation course (n = 321), 134 (42%) relapsed.
All patients that received the last consolidation course were in com-
plete remission after two induction courses and therefore none had
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F IGURE 1 Flow diagram of included and G-CSF treated patients; G-CSF, granulocyte colony-stimulating factor; HSCT, hematopoietic stem cell
transplantation; CR1, first complete remission. *Missing data on G-CSF administration in NOPHOdatabase: after AIET in six (2%) cases, after AM
in four (1%) cases, after HA1M in two (1%) cases, after HA2E1 in 11 (3%) cases, after HA3 in 10 (3%) cases, and after HA2E2 in 12 (4%) cases
received G-CSF (FLAG) as a part of treatment. The median follow-up
time starting at recovery from last consolidation course for patients
alive at last follow-up was 5.6 years (range 1.0-12.5 years). Patients
that had received G-CSF at least once during treatment had higher
risk of relapse compared to those who had not received G-CSF (5-year
cumulative incidence of relapse: 51 vs 39%, Table 3). Cumulative dose
of G-CSF above the median did not increase the risk of relapse further
(Table 3). In the continuous relationship of cumulative G-CSF dose
and risk of relapse, it appears that a plateau in the risk of relapse was
reached at a cumulative G-CSF dose of about 75-100 𝜇g/kg (Figure 2).
Increasing doses above 100 𝜇g/kg appeared to be associated with a
slight decrease in risk of relapse, but the CI is wide.
4 DISCUSSION
In this large, population-based cohort including 367 unselected pedi-
atric patients newly diagnosed with AML and treated in the Nordic
countries, Hong Kong, the Netherlands, and Belgium from 2004 to
2013,we found thatG-CSFwasusedas supportive care in about a third
of patients, but the use decreased over time. There were large differ-
ences in G-CSF use across countries and centers. Filgrastim was the
most commonly used drug and infection was the most common indi-
cation. Patients who had received G-CSF and finished treatment were
at about 50% higher risk of relapse after adjustment for themost com-
mon andwell-recognized risk factors.
G-CSF reduces the duration of neutropenia in children and adults
treated for AML, but does not seem to reduce the risk of microbi-
ologically documented infections or treatment-related mortality.13,14
Therefore, prophylactic G-CSF is not recommended in adults or chil-
dren treated for AML.15,16 In the NOPHO-AML 2004 protocol, G-
CSF was not recommended for prophylactic use, but could be consid-
ered for patients with life-threatening bacterial or fungal infections.
The DB AML-01 protocol did not include recommendations on G-CSF
use. Despite the recommendations, a third of the patients received G-
CSF, though in the majority the indication was other than prophylac-
tic. Restricting analysis to Nordic patients treated after 2009, about a
fifth had received G-CSF (Table 1). This is comparable to a recent pub-
lication from the International Berlin-Frankfürt-Münster group show-
ing that around a third of study groups use G-CSF in case of severe
infection or prolonged neutropenia.25 Infectionwas themost common
indication for G-CSF administration (Table 2), which is compatible with
the fact that the frequency of severe infections was high for patients
treated according to NOPHO-AML 2004.7 We have previously shown
that AIET and HA1M were the most toxic courses and neutrophil
recovery time was longer after AIET, FLA-Dx, and HA1M,
7,26 which
corresponds well with G-CSF being administered more frequently
after these courses. More patients treated according to NOPHO-AML
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TABLE 1 Baseline characteristics of the entire cohort and cohort stratified on G-CSF treatment
G-CSF treatment
Entire cohort Never At least once
n (%) n (%) n (%)
Patients 367 (100) 239 (65) 128 (35)
Sex Male 193 (53) 118 (49) 75 (59)
Female 174 (47) 121 (51) 53 (41)
Age Median (range) 6 (0-17) 5 (0-17) 7 (0-17)
BMI standard deviation score* Median (range) 0.0 (−4.0–3.1) 0.0 (−4.0–3.1) 0.0 (−3.8–3.0)
Country Sweden 91 (25) 61 (26) 30 (23)
Denmark 47 (13) 38 (16) 9 (7)
Norway 39 (11) 28 (12) 11 (9)
Finland 39 (11) 19 (8) 20 (16)
Iceland 5 (1) 4 (2) 1 (1)
Belgium 33 (9) 26 (11) 7 (5)
The Netherlands 68 (19) 52 (22) 16 (13)
Hong Kong 45 (12) 11 (5) 34 (27)
Protocol NOPHO-AML 2004 266 (72) 161 (67) 105 (82)
DBAML-01 101 (28) 78 (33) 23 (18)
Diagnostic year group 2004-2009 154 (42) 84 (35) 70 (55)
2010-2014 213 (58) 155 (65) 58 (45)
Diagnostic year group, Nordic countries only 2004-2009 137 (62) 81 (54) 56 (79)
2010-2013 84 (38) 69 (46) 15 (21)
WBC (109/L) at diagnosis* Median (range) 21 (1-495) 23 (1-495) 18 (1-426)
FLT3 ITD 31 (8) 24 (10) 7 (5)
Wild type/other 248 (89) 167 (70) 81 (63)
Unknown 88 (24) 48 (20) 40 (31)
Cytogenetic abnormalities* t(8;21) 61 (17) 34 (14) 27 (21)
inv(16)/t(16;16) 38 (10) 20 (8) 18 (14)
KMT2A 86 (23) 68 (28) 18 (14)
≥5% blast in bonemarrow between day 15 and start of second induction* 87 (24) 56 (23) 31 (24)
FLA-Dx as second induction 39 (11) 28 (12) 11 (9)
Treatment duration per course in days for those
who completed treatment*
Median (range) 30 (19-47) 29 (19-46) 31 (22-47)
Dose reductions of least one course§ 21 (6) 12 (5) 9 (7)
BMI, bodymass index; G-CSF, granulocyte colony-stimulating factor; ITD, internal tandem duplication;WBC, white blood count.
*BMI missing in three cases (0.8%), WBC missing in one (0.3%), cytogenetic abnormalities missing in two cases (0.5%), bone marrow blasts after the first
inductionmissing in six cases (2%), and treatment durationmissing in five cases.
§More than 20% reduction of at least one drug dose or chemotherapy interruption of more than 7 days, intrathecal treatment not included.
2004 compared to patients treated according to DB AML-01 had
received G-CSF (39 vs 23%), which could be due to DB AML-01 being
less toxic, but the two groups also differ in median diagnostic year and
institutional practices.
Patients with core binding factor leukemia received G-CSF more
often. Our group has previously shown that patients with t(8,21) had
inferior outcome before the second induction course was changed
from AM to FLA-Dx in 2011 for patients with this cytogenetics
abnormality.20 Themodel of G-CSF and risk of relapse included t(8;21)
as a covariate. There was no difference in median cumulative neu-
trophil recovery time per course according to cytogenetic or FLT3/ITD
status (Supplementary Table S2).
We found that G-CSF administration was associated with an
increased risk of relapse in our cohort of patients. In adults with AML,
a large meta-analysis showed no association of G-CSF use and risk of
relapse,13 but in children the association is not well studied. The pedi-
atric AML protocol AML-BFM 98 included randomization to either no
G-CSF or prophylactic G-CSF during induction and showed a trend for
increased relapse risk in standard-risk patients treated with G-CSF.14
In a subsequent analysis of 50 standard risk patients treated according
to the AML-BFM 98 protocol, it was found that patients overexpress-
ing thedifferentiation-defectiveG-CSFR isoform IV treatedwithG-CSF
had an increased risk of relapse.12 Our study cohort is comparable to
the standard risk group of AML-BFM 98 in that we excluded patients
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TABLE 2 G-CSF treatment per course
AIET AM FLA-Dx HA1M HA2E1 HA3 HA2E2 In total
Course given, n 367 321 39 254 343 330 325 1979
G-CSF administered, n (%)a 57 (16) 41 (13) 8 (21) 51 (20) 45 (13) 33 (10) 34 (10) 269 (14)
Drug received,b
n (%)
Filgrastim 50 (88) 32 (78) 8 (100) 40 (78) 37 (82) 22 (67) 22 (65) 211 (82)
Lenograstim 1 (2) 2 (5) 0 3 (6) 1 (2) 0 3 (9) 10 (4)
Pegfilgrastim 2 (4) 3 (7) 1 (13) 5 (10) 4 (9) 5 (15) 3 (9) 23 (9)
Missing 6 (11) 4 (10) 0 4 (8) 5 (11) 8 (24) 4 (12) 31 (12)
Cumulative dose in 𝜇g/kg,
median (range)
51 (10-245) 39 (5-200) 146 (45283) 43 (5-540) 50 (5-220) 53 (5-200) 55 (5-200) 75 (7-1460)
Indication for G-CSF,
n (%)
Infection 35 (61) 18 (44) 6 (75) 22 (43) 15 (33) 10 (30) 12 (35) 118 (44)
Neutropenia 13 (23) 17 (41) 1 (13) 19 (37) 16 (36) 8 (24) 11 (32) 85 (32)
Prophylactic 3 (5) 4 (10) 1 (13) 6 (12) 8 (18) 7 (21) 5 (15) 34 (13)
Otherc 2 (4) 0 0 0 0 0 0 2 (0.7)
Missing 4 (7) 2 (5) 0 4 (8) 6 (13) 8 (24) 6 (18) 30 (11)
Course start to
G-CSF start,
median (range)
Infection 17 (6-32) 15 (0-31) N/A 18 (13-37) 15 (10-26) 15 (3-19) 15 (7-16) 16 (0-37)
Neutropenia 18 (5-37) 17 (11-27) N/A 18 (6-35) 15 (4-31) 14 (3-40) 13 (6-35) 16 (2-40)
Prophylactic N/A N/A N/A N/A 5 (4-6) 4 (2-6) N/A 5 (2-7)
Cumulative dose in
𝜇g/kg per course,
median (range)
Infection 50 (10-145) 43 (5-120) N/A 35 (5-540) 40 (15-175) 40 (15-125) 30 (5-157) 43 (5-540)
Neutropenia 63 (20-150) 30 (5-75) N/A 45 (5-140) 38 (5-150) 53 (5-115) 60 (20-200) 45 (5-202)
Prophylactic N/A N/A N/A N/A 107 (80-220) 100 (28-200) N/A 100 (5-395)
G-CSF, granulocyte colony-stimulating factor; N/A, not applicable (median only stated for seven ormore cases).
aData onG-CSF administrationweremissing in the protocol database after AIET in six (2%) cases, after AM in four (1%) cases, after HA1M in two (1%) cases,
after HA2E1 in 11 (3%) cases, after HA3 in 10 (3%) cases, and after HA2E2 in 12 (4%) cases. In case of missing data in the protocol database, it was assumed
that the patient did not receive G-CSF.
bAfter seven courses, patients received pegfilgrastim followed by filgrastim (two patients after AIET, one patient after FLA-Dx, one patient after HA1M, two
patients after HA2E1, and one patient after HA3).
cOther indications cover severe abdominal toxicity and G-CSF given to hastenmarrow recovery.
TABLE 3 G-CSF treatment and risk of relapse
Patients who
finished
treatment (n)
Five-year cumulative
incidence of relapse
(95%CI)
CrudeHR
(95%CI) P-value
Adjustedb HR
(95%CI) P-value
Never G-CSF treated 210 39% (32-45%) 1 - 1 -
G-CSF treated 111 51% (41-60%) 1.4 (1.0-1.9) 0.07 1.5 (1.1-2.2) 0.03
G-CSF≤75 𝜇g/kga 49 52% (37-66%) 1.5 (0.9-2.3) 0.09 1.5 (1.0-2.5) 0.07
G-CSF>75 𝜇g/kga 48 47% (32-62%) 1.2 (0.8-2.0) 0.4 1.4 (0.8-2.3) 0.2
CI, confidence interval; G-CSF, granulocyte colony-stimulating factor; HR, hazard ratio.
aCumulative G-CSF dose wasmissing for 14 patients.
bAdjusted for sex, age, BMI standard deviation score, FLT3/ITD status, KMT2A rearrangements, inv(16), t(8;21), response to first induction (≥5% blasts
between day 15 and start of the second induction course [yes/no]), and any dose reductions (yes/no).
treatedwithHSCT.The report ofAML-BFM98doesnot address cumu-
lative doses of G-CSF given, but patients received 5 𝜇g/kg/day from
day 15 of first and second induction course and continued until the
absolute neutrophil count exceeded 0.5×109/L on 3 consecutive days.
Median time in neutropenia after the first induction course was 18
days and after the second induction course 11 days for G-CSF treated
and therefore we estimate the median cumulative dose to be (18+11)
× 5 = 145 𝜇g/kg. This is twice as much as the median cumulative dose
of our study, but comparable to that of those patients in our study that
received G-CSF prophylactically. Figure 2 indicates that the increasing
risk of relapsewith increasingmedian cumulativeG-CSF dose plateaus
at 75-100 𝜇g/kg. Few patients were treated with doses over this level,
hence statistical power to find the plateau threshold is limited. The
fact that a plateau is reached corresponds with a study by Inaba et al
showing that higher doses of filgrastim (10 vs 5 𝜇g/kg/day) did not fur-
ther decrease time in neutropenia.27 If higher doses of G-CSF do not
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F IGURE 2 Cumulative G-CSF dose and risk of relapse; the figure
shows the relationship of cumulative dose of G-CSF in 𝜇g/kg and
hazard ratio for relapse (solid line) with 95% confidence intervals
(dotted lines). Patients that received G-CSF but withmissing
cumulative dose (n= 14) were excluded from this analysis. Estimates
are adjusted for sex, age (continuous), BMI standard deviation score
(continuous), FLT3/ITD status (FLT3/ITD yes/no/missing), response to
first induction (≥5% blasts from day 15 to start of second induction
yes/no), and any dose reductions (yes/no). Only three patients
received cumulative G-CSF dose above 500 𝜇g/kg, and therefore the
x-axis is terminated at 500 𝜇g/kg. G-CSF, granulocyte
colony-stimulating factor
stimulate neutrophil proliferation further, it is possible that the same is
true for AML blasts.
This study needs to be interpreted in light of its limitations. The fre-
quency of G-CSF administration could be underestimated because in
case of missing registration in the protocol database, it was assumed
that the patient had not received G-CSF. However, since registration
was close to complete (<5% missing), we believe this potential bias
to be small. Also, with our nonrandomized study design, it was dif-
ficult to determine whether patients relapsed due to G-CSF treat-
ment orwere treatedwithG-CSF due to poor general condition, which
could be associated with relapse. However, we incorporated the most
common, well-established, and potential risk factors for relapse (sex,
age, BMI standard deviation score, t(8;21), inv(16), KMT2A rearrange-
ments, FLT3/ITD status, response to first induction, and dose reduc-
tions) in the statistical model and the association remained. Neverthe-
less, we acknowledge the potential for residual confounding, since it
would be impossible to incorporate into a model all the factors that
physicians use in the clinical decision of whether G-CSF should be
given. Follow-up began at the end of treatment, which separates expo-
sure and outcome in time, avoiding the confounding factor that immi-
nent relapse could result in slow bonemarrow regeneration leading to
G-CSF administration.
In conclusion, we found that supportive-care use of G-CSF was fre-
quent for patients treatedonNOPHO-AML2004andDBAML-01with
a large variation between centers. The use of G-CSF decreased over
time. Our results indicate that children that received G-CSF as sup-
portive care were at an increased risk of relapse and support the con-
cern that G-CSF usemight be harmful in pediatric AML.
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